Stanley Hazen, MD, PhD, is Biomarker Core Lab Director of C5Research, Section Head of Preventive Cardiology & Rehabilitation, Director for the Center for Cardiovascular Diagnostics and Prevention, and a staff physician in the Departments of Cell Biology and Cardiovascular Medicine at Cleveland Clinic. Dr. Hazen sees patients within the Preventive Cardiology Clinic, specializing in care of patients with hyperlipidemia, diabetes and hypertension, as well as within the Cardiovascular Rehabilitation program. His research interests include understanding the role of inflammation and oxidant stress in the pathogenesis of atherosclerosis and other inflammatory diseases, mechanisms of atherosclerosis, the biochemistry of leukocyte peroxidases, free radicals and reactive oxygen species and mechanisms of oxidative damage. Dr. Hazen is listed as a co-inventor on multiple patents for his work in identifying patients at increased risk for cardiovascular disease, diagnosing asthma, and treating inflammation and associated complications. He has been principal investigator on numerous NIH grants. Dr. Hazen has published over 180 peer-reviewed articles, invited reviews and book chapters in the fields of atherosclerosis, oxidation and inflammation chemistry, and cardiovascular disease. Dr. Hazen is on the editorial boards of Circulation, The Journal of Biological Chemistry and Free Radicals in Biology & Medicine.